Pfizer's CEO Albert Bourla said in a Sunday conference that its vaccine, which the pharmaceutical giant has been investing and developing to treat the COVID-19, has been set to release by the end of the year. Following the conference, the CEO also mentioned that the drugmakers have key data from its late-stage trial for the Food and Drug Administration by the end of October.
Bourla said Sunday that the company has already invested $1.5 billion for the development of the potential vaccine. He said if the vaccine failed to work it would be financially “painful” for the company. “At the end of the day, it’s only money. But that will not break the company, although it’s going to be painful," he said.